Cytokinetics (CYTK) News Today → The Overlooked Retirement Asset You Probably Don’t Own (From Crypto 101 Media) (Ad) Free CYTK Stock Alerts $59.53 -0.39 (-0.65%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 4:08 PM | msn.comCytokinetics to Host Muscle SeminarMay 17 at 7:30 AM | globenewswire.comCytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle BiologyMay 16 at 1:43 PM | markets.businessinsider.comBuy Rating Justified by Cytokinetics’ Aficamten Favorable Trial Data and Safety ProfileMay 16 at 1:43 PM | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK) and Alector (ALEC)May 16 at 6:30 AM | marketbeat.comCharles Schwab Investment Management Inc. Has $65.96 Million Stock Position in Cytokinetics, Incorporated (NASDAQ:CYTK)Charles Schwab Investment Management Inc. boosted its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 4.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 789,969 shaMay 16 at 5:48 AM | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Rating Reiterated by HC WainwrightMay 16 at 12:54 AM | marketbeat.comThornburg Investment Management Inc. Lowers Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Thornburg Investment Management Inc. lessened its position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 21.2% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 85,199 shares of the bioMay 15 at 7:30 AM | globenewswire.comCytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024May 14, 2024 | markets.businessinsider.comBuy Rating Justified: Cytokinetics’ Aficamten Shows Superior Efficacy in SEQUOIA-HCM Phase 3 TrialMay 14, 2024 | markets.businessinsider.comJefferies Keeps Their Buy Rating on Cytokinetics (CYTK)May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics on Aficamten’s Positive Phase 3 Trial OutcomesMay 14, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and set a $94.00 target price on shares of Cytokinetics in a report on Tuesday.May 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics on Strong SEQUOIA-HCM Study Results and Favorable Market ProspectsMay 13, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Shares Down 5.6% Cytokinetics (NASDAQ:CYTK) Trading Down 5.6%May 13, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Zimmer Biomet Holdings (ZBH), Annexon Biosciences (ANNX) and Cytokinetics (CYTK)May 13, 2024 | globenewswire.comCytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of MedicineMay 13, 2024 | globenewswire.comCytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 CongressMay 13, 2024 | americanbankingnews.comJMP Securities Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $106.00May 13, 2024 | americanbankingnews.comOppenheimer Cuts Cytokinetics (NASDAQ:CYTK) Price Target to $106.00May 13, 2024 | americanbankingnews.comCytokinetics (NASDAQ:CYTK) Given "Buy" Rating at Needham & Company LLCMay 13, 2024 | americanbankingnews.comB. Riley Comments on Cytokinetics, Incorporated's Q2 2024 Earnings (NASDAQ:CYTK)May 13, 2024 | americanbankingnews.comLeerink Partnrs Equities Analysts Reduce Earnings Estimates for Cytokinetics, Incorporated (NASDAQ:CYTK)May 11, 2024 | marketbeat.comCytokinetics, Incorporated (NASDAQ:CYTK) Shares Bought by Natixis Advisors L.P.Natixis Advisors L.P. raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 43.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,962 shares of thMay 10, 2024 | finance.yahoo.comCytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical TrialsMay 10, 2024 | finance.yahoo.comCytokinetics First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | markets.businessinsider.comCytokinetics: Buy Rating Affirmed Amid Clinical Advancements and Strategic Regulatory PlansMay 9, 2024 | markets.businessinsider.comCytokinetics: Strong Buy Rating on Promising Aficamten Prospects and Market PotentialMay 9, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Given New $106.00 Price Target at JMP SecuritiesJMP Securities decreased their price objective on Cytokinetics from $110.00 to $106.00 and set a "market outperform" rating on the stock in a research report on Thursday.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics Amid Promising Phase 3 Trial Results and Strategic FDA EngagementsMay 9, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Announces Earnings Results, Misses Expectations By $0.17 EPSCytokinetics (NASDAQ:CYTK - Get Free Report) announced its earnings results on Wednesday. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.17). The business had revenue of $0.84 million during the quarter, compared to the consensus estimate of $0.91 million. During the same quarter last year, the firm posted ($1.38) earnings per share. The firm's revenue for the quarter was down 81.8% compared to the same quarter last year.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cytokinetics’ Aficamten Ahead of Key Phase 3 Study ResultsMay 9, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Cytokinetics (CYTK)May 9, 2024 | finance.yahoo.comCytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...May 9, 2024 | finance.yahoo.comCytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Stock Rating Reaffirmed by Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $108.00 target price on shares of Cytokinetics in a report on Thursday.May 8, 2024 | investorplace.comCYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | finanznachrichten.deCytokinetics, Incorporated: Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586May 8, 2024 | globenewswire.comCytokinetics Reports First Quarter 2024 Financial ResultsMay 8, 2024 | marketbeat.comCytokinetics (NASDAQ:CYTK) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $94.00 price target on shares of Cytokinetics in a research report on Wednesday.May 8, 2024 | globenewswire.comCytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic CardiomyopathyMay 8, 2024 | globenewswire.comCytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586May 8, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 15,547 Shares of StockMay 8, 2024 | insidertrades.comFady Ibraham Malik Sells 15,547 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockMay 8, 2024 | finance.yahoo.comInsider Sale at Cytokinetics Inc (CYTK): EVP Research & Development Fady Malik Sells SharesMay 7, 2024 | globenewswire.comCytokinetics to Hold Annual Meeting of StockholdersMay 7, 2024 | investorplace.comBiotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareMay 6, 2024 | marketbeat.comLisanti Capital Growth LLC Makes New $4.22 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)Lisanti Capital Growth LLC bought a new position in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund bought 50,480 shares of the biopharmaceutical company's stock, valued at approximatelyMay 4, 2024 | marketbeat.comFisher Asset Management LLC Makes New $44.75 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK)Fisher Asset Management LLC purchased a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 535,954 shares of the biopharmaceutical company's stock, vMay 3, 2024 | marketbeat.comRussell Investments Group Ltd. Cuts Stake in Cytokinetics, Incorporated (NASDAQ:CYTK)Russell Investments Group Ltd. reduced its stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) by 12.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 252,122 shares of the biopharmaceutical company's stoMay 2, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news. Register For The Webinar To Discover CYTK Media Mentions By Week CYTK Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CYTK News Sentiment▼0.400.50▲Average Medical News Sentiment CYTK News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CYTK Articles This Week▼297▲CYTK Articles Average Week Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Intra-Cellular Therapies News Jazz Pharmaceuticals News Elanco Animal Health News Blueprint Medicines News Cerevel Therapeutics News Ionis Pharmaceuticals News Ascendis Pharma A/S News Apellis Pharmaceuticals News Legend Biotech News Organon & Co. News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CYTK) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersObama’s Forever Term [exposed]Porter & CompanyThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingMost important medical advance in 100 yearsThe Oxford ClubThe Presidential candidate you should REALLY be worried aboutStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsClaim Your Complimentary Bitcoin RewardCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
